Presentation About Phase 3 Trial of DCVax-L for Glioblastoma Today At New York Academy of Sciences To Be Available...

BETHESDA, Md., May 10, 2024 /PRNewswire/ -- Northwest Biotherapeutics NWBO (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that, as previously announced, a presentation entitled Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma will be made today at 11:10 a.m., at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences. The presentation will be made by Dr. Paul Mulholland of University College Hospital.

This presentation can be viewed virtually by registering online at the Academy's website at https://events.nyas.org/event/28ca5e39-51a7-4e73-be3d-78089c92d596/summary

Additionally, the slides used in the presentation will be posted online concurrently with or promptly following the presentation at Virtualtrials.org/Dcvax. The slides will not be posted on the Company's website.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an orphan disease. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.